fda tirzepatide compounding warning 2024 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Tirzepatide Shortage Ends - American

You can submit this letter to Aetna with any other documents required for the prior authorization

The gap between doing it right and stopping at week six due to unbearable side effects comes down to understanding why the escalation schedule exists

I dont, for instance, want to blow my drug budget prescribing edoxaban just because some grubby deal has been done by the DOH

Treatments that mimic GLP-1 can assist with type 2 diabetes and weight management, but consulting with a healthcare provider is essential before starting

To qualify, individuals typically need to have type 2 diabetes

van Kaam, MD, PhD, neonatologist, Emma Childrens Hospital, Amsterdam University Medical Centers, location University of Amsterdam, Department of Neonatology, Amsterdam Reproduction & Development, Amsterdam, the Netherlands